NCT04843839View on ClinicalTrials.gov

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Congenital Hereditary Endothelial Dystrophy of Cornea
Interventions
DRUG

Nepafenac 0.1% Oph Susp

Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months

DRUG

Refresh Tears 0.5% Lubricant Eye Drops

Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months

Trial Locations (1)

500034

RECRUITING

L V Prasad Eye Institute, Hyderabad

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

L.V. Prasad Eye Institute

OTHER